UCB (OTCMKTS:UCBJY) Shares Gap Down on Analyst Downgrade

UCB SA (OTCMKTS:UCBJY) shares gapped down prior to trading on Monday after Barclays downgraded the stock from a strong-buy rating to a hold rating. The stock had previously closed at $158.72, but opened at $150.53. UCB shares last traded at $151.3950, with a volume of 26,509 shares traded.

UCBJY has been the subject of a number of other research reports. Zacks Research lowered shares of UCB from a “hold” rating to a “strong sell” rating in a research report on Thursday, June 11th. Wolfe Research upgraded shares of UCB to a “strong-buy” rating in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

UCB Price Performance

The stock’s 50-day moving average is $145.55 and its two-hundred day moving average is $147.39. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.